Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
The Netherlands Cancer Institute
The investigators want to set up this study in analogy with the comparison study which was conducted before the introduction of ICG-99mTc-Nanocolloid (99mTc-Nanocoll vs. ICG-99mTc-Nanocoll (NL26699.031.09 -N09DRF). In particular, the investigators want to validate that the hybrid ICG-99m Tc-Nanoscan shows the same preoperative gland involvement on preoperative lymphoscintigraphy and that the intraoperative signal intensities remain the same. All this to maintain the level of current care.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient who will undergo a sentinel node procedure in routine care.
Patients \> 18 years;
Patients presenting with:
a primary cutaneous melanoma of head/neck or upper part of the trunk or extremities;
OR patients presenting with a primary oral cavity malignancy T1-2N0
OR patients with primary penile cancer
Patients with clinical N0 stage;
Patients scheduled for a sentinel node biopsy prior to (re-)excision of the primary lesion;
Patients in which ICG-99mTc-nanoscan would be used in routine care or a research setting
You may not be if
Patients with known allergy to patent blue dye or nanocolloid;
Patients who are pregnant or breast-feeding mothers;
History of hypersensitivity reactions to products containing human serum albumin;
History of iodine allergy
Hyperthyroid or thyroidal adenoma
Kidney insufficiency
Incapacity or unwillingness of participant to give written informed consent;
Clareo Health | Validation of ICG-99mTc-nanoscan as Hybrid Tracer for Sentinel Node Biopsy
